MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
MeiraGTx Holdings' MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson's disease ( PD ) met its primary study objective of safety and tolerability. The stock soared 14.9% in response to the news.
| Ticker |
Sentiment |
Impact |
|
ALNY
|
Neutral
|
16 %
|
|
FOLD
|
Neutral
|
16 %
|
|
ANIP
|
Somewhat Bullish
|
26 %
|
|
MGTX
|
Neutral
|
46 %
|
